Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb


UCB FY Consensus Product Sales Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e Peak Sales NPV
Core Products                  
Cimzia 1,712 1,800 1,888 1,946 1,941 1,776 1,522   5,080
Vimpat 1,322 1,449 1,549 1,382 867 682 556   2,580
Keppra  770 764 715 647 592 546 499   2,210
Briviact 221 295 364 431 492 545 583 627 1,761
Neupro 319 301 261 217 185 159 136   494
Potential new Product Launches
(global sales, non-risk adj.)
                 
Evenity (romosozumab)   399  582 731 865 989 1,084 1,297 2,082
Nayzilam   23 45 66 87 104 113 141 334
Bimekizumab   0 98 355 672 1,010 1,372  2,323  5,324
Zilucoplan   0 0 39 153 315 490 1,116 2,235
Rozanolixizumab    0 0 16 88 198 367 1,058 1,899
Dapimab   0 7 16 34 60 109    
Staccato alprazolam   0 0 1 3 42 120    
UCB0107 (Anti-Tau)   0 0 0 13 78 138    

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 5,020 5,306 5,480 5,381
Revenue  4,913 5,242 5,513 5,678 5,570
Adjusted EBIT 1,118  1,100 1,258 1,440 1,406
Adjusted EBITDA 1,431  1,441 1,608 1,786 1,761
Net Profit*  792 728 906 1,076 1,054
Core EPS (€) 5.20  4.91 5.66 6.48 6.40

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e Peak Sales NPV
Core Products                  
Cimzia 1,712 1,804 1,906 1,973 1,985 1,794 1,516   5,035
Vimpat 1,322 1,452 1,540 1,401 909 684 539   2,564
Keppra 770 761 714 641 592 539 487   2,102
Briviact 221 294 360 423 482 537 584 599 1,709
Neupro 319 305 256 214 188 162 135   519
Potential new Product Launches
(global sales, non-risk adj.)
                 
Evenity (romosozumab)   403 580 698 837 1,003 1,091 1,300 1,932
Nayzilam   25 48 68 89 107 113 150 284
Bimekizumab   0 84 354 700 1,044 1,329 2,303 5,094
Zilucoplan   0 0 0 140 299 447 1,095 1,957
Rozanolixizumab (Rozimab)   0 0 0 83 170 353 985 1,708
Dapimab   0 0 0 0 0 63    
Staccato alprazolam   0 0 0 0 30 88    
UCB0107 (Anti-Tau)   0 0 0 0 82 129    

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 5,040 5,346  5,576  5,439
Revenue  4,913 5,272 5,536 5,739 5,639
Adjusted EBIT 1,118  1,078 1,232 1,461 1,501
Adjusted EBITDA 1,431 1,426 1,620 1,805 1,818
Net Profit*  792  729 934 1,095 1,110
Core EPS (€) 5.20 4.92 5.76 6.47
6.48

*attributable to UCB shareholders

Downloads:
UCB HY 2020 & FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 26 November 2020



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.